FOR IMMEDIATE RELEASE
CONSHOHOCKEN, PA – April 18, 2006 – Fast Track Systems, Inc., a leading provider of clinical trial software designed to reduce the cost and improve productivity within clinical trial operations, today announced that Forest Laboratories, Inc. (NYSE: FRX) has selected TrialSpace Grants Manager® to assist in its global clinical trial costing activities.
Using Grants Manager, Forest Laboratories will have access to the most comprehensive industry-wide data on protocol pricing, investigator fees, and site expenses by specific Therapeutic Area, Phase, and Geography which may reduce the time and expense associated with negotiating OIG compliant investigator contracts.
"Forest Laboratories has consistently delivered impressive growth from their marketed products and is an innovator in drug discovery and development," remarked Ed Seguine, CEO, Fast Track Systems. "We're pleased to include them as yet another Top 20 pharmaceutical company among our existing base of over 60 customers. We look forward to collaborating with Forest as they pursue an aggressive product development agenda."
About Fast Track Systems
Fast Track's products improve productivity, increase compliance, and reduce costs by solving problems associated with the operational aspects of clinical trial design and execution. TrialSpace Designer® ensures greater consistency and transparency in trial design by capturing protocol content as reusable data that can be utilized by other clinical systems and leveraged for related purposes. Grants Manager® and CROCAS® draw from over 25,000 finalized protocols, 240,000 negotiated grants, and 4,000 CRO contracts to ensure subscribers understand the true cost and compliance consequences when negotiating clinical agreements. Visit www.fast-track.com for more information about our products and services.
About Forest Labs and Its Products
Forest Laboratories' growing line of products includes: Lexapro® (escitalopram oxalate), an SSRI antidepressant indicated for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder in adults; Namenda® (memantine HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar® * (olmesartan medoxomil), an angiotensin receptor blocker indicated for the treatment of hypertension; Benicar* HCT® (olmesartan medoxomil hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral® * (acamprosate calcium), a glutamate receptor modulator, indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation in combination with psychosocial support; and Combunox™ (Oxycodone HCl and Ibuprofen), an opioid and NSAID combination indicated for the short-term management of acute, moderate to severe pain.
* Benicar is a registered trademark of Sankyo Pharma, Inc., and Campral is a registered trademark under license from Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany